Videos | Bringing pharma’s top innovators to your screen

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

Oncology

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

R&D

Sponsored

Patient population first: the strategy behind country decisi...

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

Oncology

ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad

In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto

Oncology

ASCO 2026: All about DNA damage response, with Luke Piggot

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Sales & Marketing

Interview at JPM26 with Helen Sabzevari and Greg Skalicky

Rewiring commercialisation to meet the moment, with Helen Sa...

At the Informa Biotech Showcase at JPM2026, EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, discuss new commercialisation.

Digital

Interview at Reuters Pharma EU with Florian Schnappauf, Veeva

From data to deployment: Navigating AI adoption in pharma wi...

Explore our video interview for expert tips on AI adoption in pharma, featuring Veeva.

Digital

Inizio Ignite, STEM AI video feature image

Sponsored

STEM AI: Delivering intelligent data-led HCP interactions

In a new sponsored video, pharmaphorum spoke with experts from STEM, an Inizio Ignite company, about STEM AI

Market Access

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Oncology

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

Oncology

ASCO 2026: All about DNA damage response, with Luke Piggot

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Patients

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

R&D

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

R&D

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

Taking the microbiome seriously, with Sam Possemiers

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Turning recruitment potential into enrolment reality

Decentralisation by design: Bringing the trial closer withou...

Patient population first: the strategy behind country decisi...

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad

ASCO 2026: All about DNA damage response, with Luke Piggot

Biotech is back, with Craig Ackerman

Rewiring commercialisation to meet the moment, with Helen Sa...

From data to deployment: Navigating AI adoption in pharma wi...

STEM AI: Delivering intelligent data-led HCP interactions

Making direct-to-patient work, with Matt Wadyka

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

ASCO 2026: All about DNA damage response, with Luke Piggot

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Making direct-to-patient work, with Matt Wadyka

Taking the microbiome seriously, with Sam Possemiers

Turning recruitment potential into enrolment reality

Decentralisation by design: Bringing the trial closer withou...

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks